A. Michael Davidson

"The full data will hopefully put in full perspective that there weren't any harmful effects at all," says A. Michael Davidson, executive medical director at Radiant Research."This was a population that was so well treated that there wasn't really any opportunity to see any difference."

He says that FH patients are no longer a good population to use in these studies.He points out that LDL lowering is a main driver of the benefit of these drugs.